OPERATING_VBG
ENVIRONMENT_NOMZ
REGULATION_NOMZ
The_DT
international_JJ
medical_JJ
device_NN
industry_NN
is_VPRT [SPAU] [PASS]
highly_AMP
regulated_VBN
._.
Regulatory_NN
requirements_NOMZ
are_VPRT [BEMA]
a_DT
major_JJ
factor_NN
in_PIN
determining_VBG [SUAV] [PRIV]
whether_IN [WHCL]
substances_NN
and_PHC
materials_NN
can_POMD
be_VB [PASS]
developed_VBN
into_PIN
marketable_JJ
products_NN
and_CC
the_DT
amount_NN
of_PIN
time_NN
and_PHC
expense_NN
that_TSUB
shouldbe_VPRT
allotted_VBN
to_PIN
suchdevelopment_NOMZ
._.
National_NN
regulatory_JJ
authorities_NOMZ
administer_VPRT
and_PHC
enforce_VPRT
a_DT
complex_JJ
series_NN
of_PIN
laws_NN
and_PHC
regulations_NOMZ
that_TSUB
govern_VPRT
the_DT
testing_GER
,_,
approval_NN
,_,
manufacturing_GER
,_,
labeling_VBG
,_,
marketing_GER
and_PHC
sale_NN
of_PIN
healthcare_NN
and_CC
pharmaceutical_JJ
products_NN
._.
They_TPP3
also_RB
review_VPRT
data_NN
supporting_VBG [WZPRES]
the_DT
safety_NN
and_PHC
efficacy_NN
of_PIN
such_JJ
products_NN
._.
Of_PIN
particular_JJ
importance_NN
is_VPRT [BEMA]
the_DT
requirement_NOMZ
in_PIN
many_QUAN
countries_NN
that_TOBJ
products_NN
be_VB [PASS]
authorised_VBN
or_CC
registered_VBN
prior_RB
to_TO
manufacture_VB
,_,
marketing_GER
or_CC
sale_NN
and_CC
that_DEMO
such_JJ
authorisation_NOMZ
or_CC
registration_NOMZ
be_VB [SPAU] [PASS]
subsequently_TIME
maintained_VBN [PUBV]
._.
The_DT
major_JJ
regulatory_JJ
agencies_NN
for_PIN
Smith_NN
&_CC
Nephews_NN
products_NN
are_VPRT [BEMA]
the_DT
FDA_NN
in_PIN
the_DT
US_FPP1
,_,
the_DT
Medicines_NN
and_PHC
Healthcare_NN
products_NN
Regulatory_NN
Agency_NN
in_PIN
the_DT
UK_NN
and_CC
the_DT
Ministry_NN
for_PIN
Health_NN
Labor_NN
and_PHC
Welfare_NN
in_PIN
Japan_NN
._.
Payment_NOMZ
for_PIN
many_QUAN
medical_JJ
device_NN
products_NN
is_VPRT [BYPA]
governed_VBN
by_PIN
reimbursement_NOMZ
tariff_NN
agencies_NN
ineach_VPRT
individualcountry_NN
._.
The_DT
trend_NN
in_PIN
recent_JJ
years_NN
has_VPRT [PEAS]
been_VBN [BEMA]
towards_PIN
greater_JJ
regulation_NOMZ
and_CC
higher_JJ
standards_NN
of_PIN
technical_JJ
appraisal_NN
,_,
which_WDT [SERE]
generally_RB
entail_VPRT
lengthy_JJ
inspections_NOMZ
for_PIN
compliance_NN
with_PIN
appropriate_JJ
standards_NN
,_,
including_VBG
regulations_NOMZ
such_JJ
as_IN
good_JJ
manufacturing_GER
practices_NN
._.
Smith_NN
&_CC
Nephew_NN
believes_VPRT [PRIV]
that_THVC
these_DEMO
recent_JJ
changes_NN
will_PRMD
not_XX0
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
condition_NOMZ
and_CC
the_DT
results_NN
of_PIN
operations_NOMZ
._.
All_QUAN
significant_JJ
facilities_NOMZ
within_PIN
the_DT
Group_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
regular_JJ
internal_JJ
audit_NN
for_PIN
medical_JJ
device_NN
regulatory_JJ
compliance_NN
with_PIN
national_JJ
and_CC
Group_NN
standards_NN
and_PHC
policies_NN
._.
Smith_NN
&_CC
Nephew_NN
believes_VPRT [PRIV]
that_THVC
the_DT
Groups_NN
operations_NOMZ
currently_RB
comply_VPRT
in_PIN
all_QUAN
material_NN
respects_VPRT
with_PIN
applicable_JJ
environmental_JJ
laws_NN
and_PHC
regulations_NOMZ
._.
Although_CONC
the_DT
Group_NN
continues_VPRT
to_TO
make_VB
capital_NN
expenditure_NN
for_PIN
environmental_JJ
compliance_NN
,_,
it_PIT
is_VPRT
not_XX0
currently_RB
aware_PRED
of_PIN
any_QUAN
significant_JJ
expenditure_NN
that_TSUB
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
as_CONJ
a_NULL
result_NULL
of_PIN
suchlaws_NN
and_PHC
regulationsthat_NN
wouldhave_VPRT
a_DT
material_NN
adverse_JJ
impact_NN
uponthe_NN
Groups_NN
financialcondition_NOMZ
._.
PRODUCT_NN
LIABILITY_NOMZ
The_DT
Group_NN
monitors_VPRT
the_DT
safety_NN
of_PIN
its_PIT
products_NN
from_PIN
initial_JJ
product_NN
development_NOMZ
through_PIN
to_PIN
product_NN
use_NN
or_CC
application_NOMZ
._.
In_CONJ
addition_NULL
,_,
the_DT
businesses_NOMZ
of_PIN
the_DT
Group_NN
analyze_VB
on_PIN
a_DT
worldwide_JJ
basis_NN
reports_NN
of_PIN
adverse_JJ
reactions_NOMZ
and_PHC
complaints_NN
relating_VBG [WZPRES]
to_PIN
its_PIT
products_NN
._.
Each_QUAN
business_NOMZ
reviews_VPRT
these_DEMO
adverse_JJ
reactions_NOMZ
and_PHC
complaints_NN
and_CC
any_QUAN
safety_NN
matters_VPRT
arising_VBG
with_PIN
independent_JJ
medical_JJ
advisors_NN
._.
These_DEMO
conclusions_NN
are_VPRT [SPAU] [BYPA]
subsequently_TIME
reviewed_VBN
by_PIN
the_DT
Groups_NN
independent_JJ
medical_JJ
advisor_NN
._.
Product_NN
liability_NOMZ
is_VPRT [BEMA]
a_DT
commercial_JJ
risk_NN
for_PIN
the_DT
industry_NN
of_PIN
which_WDT [PIRE]
the_DT
Group_NN
is_VPRT [BEMA]
a_DT
part_NN
,_,
particularly_RB
in_PIN
the_DT
US_FPP1
._.
Smith_NN
&_CC
Nephew_NN
has_VPRT [PEAS]
implemented_VBN
systems_NN
it_PIT
believes_VPRT [PRIV]
are_VPRT [BEMA]
appropriate_PRED
in_PIN
respect_NN
of_PIN
loss_NN
control_NN
techniques_NN
._.
These_DEMP
include_VPRT
reporting_VBG [PUBV]
mechanisms_NN
to_TO
ensure_VB [SUAV] [PRIV]
early_TIME
notification_NOMZ
of_PIN
complaints_NN
and_CC
a_DT
legal_JJ
department_NOMZ
which_WDT [WHSUB]
manages_VPRT
and_CC
lawsuits_NN
._.
The_DT
Group_NN
carries_VPRT
product_NN
liability_NOMZ
insurance_NN
to_TO
cover_VB
exposure_NN
as_IN
far_PLACE
as_IN
practicable_JJ
._.
With_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
macrotextured_JJ
product_NN
liability_NOMZ
claim_NN
,_,
discussed_VBN
under_IN
Legal_NN
Proceedings_GER
,_,
and_ANDC
Risk_NN
Factors_NN
instances_NN
of_PIN
loss_NN
to_PIN
the_DT
Group_NN
arising_VBG [WZPRES]
from_PIN
product_NN
liability_NOMZ
claims_NN
have_VPRT [PEAS]
been_VBN [PASS]
covered_VBN
either_CC
directly_RB
by_PIN
the_DT
Group_NN
or_CC
by_PIN
insurance_NN
._.
Apart_RB
from_PIN
the_DT
macrotextured_JJ
claims_NN
,_,
there_EX
are_VPRT
no_SYNE
individual_JJ
product_NN
liability_NOMZ
claims_NN
,_,
and_ANDC
no_SYNE
group_NN
of_PIN
similar_JJ
claims_NN
,_,
that_DEMP
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
onthe_NN
Groups_NN
financialposition_NOMZ
._.
There_EX
can_POMD
be_VB
no_SYNE
assurance_NN
that_TOBJ
consumers_NN
,_,
particularly_RB
in_PIN
the_DT
US_FPP1
,_,
will_PRMD
not_XX0
bring_VB
product_NN
liability_NOMZ
or_CC
related_VBN
claims_NN
that_TSUB
would_PRMD
have_VB
a_DT
material_NN
adverse_JJ
effect_NN
on_PIN
the_DT
Groups_NN
financial_JJ
position_NOMZ
or_CC
results_NN
of_PIN
operations_NOMZ
in_PIN
the_DT
future_NN
or_CC
that_THVC
the_DT
Group_NN
will_PRMD
continue_VB
to_TO
resolve_VB [SUAV]
such_JJ
claims_NN
within_PIN
insurance_NN
limits_NN
in_PIN
view_NN
of_PIN
changing_VBG
legal_JJ
doctrines_NN
and_PHC
attitudes_NN
regardingsuchmatters_NN
._.
See_VB [PRIV]
Risk_NN
Factors_NN
and_PHC
Loss_NN
of_PIN
Reputation_NOMZ
._.
11_CD
RISK_NN
MANAGEMENT_NOMZ
Smith_NN
&_CC
Nephews_NN
products_NN
include_VPRT
implantable_JJ
devices_NN
but_CC
are_VPRT
not_XX0
life_NN
support_NN
medical_JJ
devices_NN
._.
If_COND
these_DEMO
devices_NN
malfunction_NOMZ
,_,
they_TPP3
could_POMD
damage_VB
or_CC
impair_VB
the_DT
repair_NN
of_PIN
body_NN
functions_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
the_DT
Groups_NN
quality_NOMZ
,_,
regulatory_JJ
and_PHC
medical_JJ
controls_NN
and_PHC
insurance_NN
cover_NN
is_VPRT [BEMA]
adequate_PRED
and_PHC
appropriate_PRED
for_PIN
this_DEMO
class_NN
of_PIN
products_NN
._.
The_DT
Groups_NN
reputation_NOMZ
is_VPRT [BEMA]
crucially_RB
dependent_PRED
on_PIN
strong_JJ
performance_NN
in_PIN
this_DEMO
area_NN
and_CC
on_PIN
appropriate_JJ
crisismanagement_NOMZ
if_COND
a_DT
serious_JJ
medical_JJ
shouldoccur_NN
._.
The_DT
Board_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
of_PIN
the_DT
Groups_NN
systems_NN
of_PIN
risk_NN
management_NOMZ
and_CC
internal_JJ
control_NN
and_CC
for_PIN
reviewing_VBG
their_TPP3
effectiveness_NOMZ
._.
These_DEMO
systems_NN
,_,
which_WDT [SERE]
accord_NN
with_PIN
the_DT
Turnbull_NN
Guidance_NN
and_CC
have_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
place_NN
for_PIN
2005_CD
and_CC
to_PIN
the_DT
date_NN
of_PIN
approval_NN
of_PIN
the_DT
report_NN
and_PHC
accounts_NN
,_,
involve_VB
:_:
the_DT
identification_NOMZ
,_,
evaluation_NOMZ
and_PHC
management_NOMZ
of_PIN
key_JJ
risks_NN
through_PIN
a_DT
Risk_NN
Committee_NN
,_,
whichreports_NN
to_PIN
the_DT
Board_NN
annually_RB
:_:
business_NOMZ
reviews_NN
by_PIN
the_DT
Board_NN
:_:
and_ANDC
the_DT
review_NN
by_PIN
the_DT
Audit_NN
Committee_NN
of_PIN
internal_JJ
financial_JJ
controls_NN
and_CC
the_DT
risk_NN
management_NOMZ
process_NN
._.
These_DEMO
systems_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
by_PIN
the_DT
Board_NN
._.
Whilst_OSUB
not_XX0
providing_VBG
absolute_JJ
assurance_NN
against_PIN
material_NN
misstatements_NOMZ
or_CC
loss_NN
,_,
these_DEMO
systems_NN
are_VPRT [PASS]
designed_VBN
to_TO
identify_VB
and_PHC
manage_VB
those_DEMO
risks_NN
that_TSUB
could_POMD [SPAU]
adversely_RB
impact_VB
the_DT
achievement_NOMZ
of_PIN
the_DT
Groups_NN
objectives_NN
._.
The_DT
Group_NN
maintains_VPRT [PUBV]
insurance_NN
against_PIN
product_NN
,_,
employers_NN
and_PHC
directors_NN
and_PHC
officers_NN
liabilities_NOMZ
,_,
and_ANDC
physical_JJ
and_PHC
consequential_JJ
loss_NN
,_,
subject_JJ
to_PIN
limits_NN
and_PHC
deductibles_NN
._.
The_DT
Group_NN
maintains_VPRT [PUBV]
liability_NOMZ
provisions_NN
to_TO
cover_VB
known_JJ
uninsured_JJ
risks_NN
._.
The_DT
Group_NN
has_VPRT [PEAS]
been_VBN [PASS]
advised_VBN
that_DEMO
three_CD
insurers_NN
have_VPRT [PEAS]
declined_VBN
coverage_NN
for_PIN
macrotextured_JJ
knee_NN
claims_NN
._.
